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A B S T R A C T
Objectives: To present long-term outcome and to identify predictors of seizure freedom after vagus nerve
stimulation (VNS).
Methods: All patients who had undergone VNS implantation in the Epilepsy Centre Bethel were
retrospectively reviewed. There were 144 patients who had undergone complete presurgical evaluation,
including detailed clinical history, magnetic resonance imaging, and long-term video-EEG with ictal and
interictal recordings. After implantation, all patientswere examined at regular intervals of 4weeks for 6–
9 months. During this period the antiepileptic medication remained constant. All patients included in
this study were followed up for a minimum of 2 years.
Result: Ten patients remained seizure-free for more than 1 year after VNS implantation (6.9%). Seizures
improved in 89 patients (61.8%) but no changes were observed in 45 patients (31.3%). The following
factors were signiﬁcant in the univariate analysis: age at implantation, multifocal interictal epileptiform
discharges, unilateral interictal epileptiform discharge, cortical dysgenesis, and psychomotor seizure.
Stepwise multivariate analysis showed that unilateral interictal epileptiform discharges (IEDs),
P = 0.014, HR = 0.112 (95% CIs, 0.019–0.642), cortical dysgenesis P = 0.007, HR = 0.065 (95% CIs,
0.009–0.481) and younger age at implantation P = 0.026, HR = 7.533 (95% CIs 1.28–44.50) were
independent predictors of seizure freedom in the long-term follow-up.
Conclusion: VNS implantation may render patients with some forms of cortical dysgenesis
(parietooccipital polymicrogyria, macrogyria) seizure-free. Patients with unilateral IEDs and earlier
implantation achieved the most beneﬁt from VNS.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Despite active pharmacological therapy in the management of
epileptic disorders, satisfactory seizure control, even with optimal
drug administration, still cannot be achieved in 30–40% of the
patients. Some of these patients can beneﬁt from resective
surgery.1 Surgical therapy achieves long-term control in 50–80%
of patients.2–4 Physiological and anatomical limitations such as
proximity to the eloquent cortex, false localization of EEG and dual
pathology in the remaining patients have been linked to surgical
failure. For those who are not candidates for epileptic focus
resection, or for those who have not beneﬁted from surgery, VNS-* Corresponding authors at: Klinik Mara, Maraweg 21, 33617 Bielefeld, Germany.
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doi:10.1016/j.seizure.2010.03.002therapy has been shown to be an effective alternative approach.5
Since the ﬁrst human implantation of a VNS device in 1988
reported by Penry, more than 55,000 patients have received VNS-
therapyworldwide.6 The efﬁcacy of VNS in treating focal epilepsies
and various types of generalized epilepsies, including idiopathic
generalized epilepsy and Lennox–Gastaut syndrome, has been
demonstrated in numerous studies.7 The predictors of seizure
freedom after VNS implantation are still unknown. Our aim was to
assess VNS outcome in a large group of patients and determine the
predictors of seizure freedom in long-term follow-up.
2. Methods
2.1. Patient selection
In this retrospective study, all patients with medically
refractory epilepsy who had a VNS system implanted at the
Bethel Epilepsy Centre fromMay 2000 to April 2007were included.vier Ltd. All rights reserved.
Table 1
Summary of clinical characteristics and predisposing factors in the patient group.
Variables All patients N=144 Seizure-free N=10 Non-seizure-free N=134 Sig.
Age at onset (years) 6.36.7 3.13.2 6.66.9 0.114
Age at implantation (years) 23.713.4 16.210.8 24.313.5 0.026
Epilepsy duration (years) 17.410.6 13.18.1 17.710.7 0.189
Follow-up (months) 36.112.2 33.413.1 36.212.1 0.479
Etiology
MCD 44 (30.6%) 5 (50%) 39 (29.1%)
Tumour 5 (3.5%) 0 (0%) 5 (3.7%)
Encephalitis 8 (5.6%) 0 (0%) 8 (6%)
Lennox-Gastaut syndrome (LGS) 16 (11.1%) 0 (0%) 16 (11.9%)
Hippocampal sclerosis (HS) 7 (4.9%) 0 (0%) 7 (5.2%)
Cerebral infarction 3 (2.1%) 0 (0%) 3 (2.2%)
Unknown 61 (42.4%) 5 (50%) 56 (41.8%)
Predisposing factors
Family history 12 (8.3%) 0 12 (9%) 0.407
CNS infection 12 (8.3%) 0 12 (9%) 0.407
Congenital anomaly 14 (9.7%) 3 (30%) 11 (8.2%) 0.059
Febrile convulsion 11 (7.6%) 0 11 (8.2%) 0.440
Head trauma 4 (2.8%) 0 4 (3%) 0.747
History of TLR 11 (7.6%) 1 (10%) 10 (7.5%) 0.560
History of extra TLR 15 (10.4%) 0 15 (11.2%) 0.320
TLR=Temporal lobe resection.
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not been followed up for at least 2 years, and patients who had not
undergone a complete presurgical evaluation including a detailed
clinical history, MRI, and long-term video-EEG with ictal and
interictal recordings. Of 144 patients (67 male and 77 female), the
mean age at seizure onset was 6.3  6.7 years (range 0.1–44 years)
and mean age at surgery was 23.7  13.4 (range 3–65 years), and the
mean duration of epilepsy was 17.4  10.6 years (range 5–56 years).
The mean follow-up duration was 36.1  12.2 months (range 24–71
months). Table 1 shows a summary of clinical characteristics and
predisposing factors in the patient group.
2.2. Presurgical evaluation
In patients who were considered to be possible candidates for
epilepsy surgery, a detailed neurological history was taken and the
resistance to AEDs was evaluated. A high resolution MRI was
carried out on all patients. Patients underwent continuous video-
EEG monitoring lasting 2–7 days. In all patients except small
children, psychiatric and neuropsychological examinations and a
social assessment were undertaken. Findings of the presurgical
evaluation were discussed at a multidisciplinary case conference,
where decisions were made about the possibility and type of brain
surgery or VNS, or alternatively, the need for further investigations.
2.3. Vagus nerve stimulation
Stimulation of the left vagal nerve was carried out using an NCP
system (Cyberonics Inc., Houston, TX, USA). Stimulation was
initiated in the immediate postoperative period, using the
parameters current: 0.25 mA, frequency: 30 Hz, pulse width:
500 ms, 30-s signal on time, 5-min signal off time.
Patients in whom a vagus nerve stimulator had been implanted
were examined at regular intervals of 4 weeks for 6–9 months.
During this period the antiepilepticmedication remained constant.
At each visit the current was gradually increased in steps of
0.25 mA and changes of the seizure situation as well as side effects
due to VNS stimulation were assessed. The current was gradually
increased until seizure freedom or the maximal possible output of
3.5 mA was reached. It was tried to obtain at least 1.5 mA unless
the patient did not tolerate this current intensity. The other device
parameters were kept unchanged during this period. If patients
showed no improvement of their seizures for 0.5–1 year afterimplantation, despite increasing the output current, the signal on
time was changed from 30 to 7 s, the signal off time from 5 min to
30 s As long as the stimulus parameters were adjusted the
concomitant antiepileptic drug treatment was altered only if the
seizure situation worsened or drug induced side effects occurred.
Patients were additionally provided with a magnet allowing
stimulation by themselves or by caregiver in the case of an aura or
seizure. The output current induced by the magnet was
programmed to be 0.25 mA higher than the automatically
delivered intensity, and had a pulse width of 500 ms for a period
of 60 s.
2.4. Data collection
Demographic data, seizure semiology, EEG (ictal and interictal),
neuroimaging data, and epilepsy syndrome were the variables
investigated. Data were obtained from the patients’ ﬁles and
medical records. In addition, EEG data were taken from non-
invasive continuous video-EEG monitoring. Preoperative 32–64
channel EEG recordings were used; electrodes were placed
according to the 10–20 system with the number of electrodes
and their placement individually varied depending on the
suspected epileptogenic region and side. The location and
frequency of IED were assessed by visual analysis of interictal
EEG samples of 2-min duration per hour.
2.5. Neuroimaging modalities
Patients underwent MR imaging performed with a 1.5 T
magnet, inwhich a speciﬁc protocol for epilepsy patientswas used.
Additional imaging methods included positron emission tomo-
graphy, single photon emission computed tomography scanning,
and proton MR spectroscopy. However, the results of these
investigations were not evaluated in the present study.
2.6. Outcome assessment
Seizure outcome was assessed at regular postoperative visits.
The basic follow-up program for all patients was scheduled for 3
months, 6 months, 2 years and then at regular intervals after 2
years. Depending on the effect of VNS, patients were assigned to
one of three outcome groups: seizure-free (complete seizure
freedom without aura), improvement (50% seizure reduction,)
Table 2
Types of seizures, MRI ﬁnding and type of IED.
All patients 144 Seizure-free 10 Non-seizure-free 134 Sig.
Type of seizure
Presence of auras 54 (37.5%) 2 (20%) 52 (38.8%) 0.202
Psychomotor seizure 38 (26.4%) 0 (0%) 38 (28.4%) 0.042
Tonic seizure 91 (63.2%) 7 (70%) 84 (62.7%) 0.462
Hypermotor seizure 24 (16.7%) 1 (10%) 23 (17.2%) 0.478
Clonic seizure 27 (18.8%) 4 (40%) 23 (17.2%) 0.092
Myoclonic seizure 50 (34.7%) 3 (30%) 47 (35.1%) 0.520
Secondary generalized 88 (61.1%) 5 (50%) 83 (61.9%) 0.335
Atypical absence 29 (20.1%) 2 (20%) 27 (20.1%) 0.676
MRI ﬁnding
Non-lesional 73 (50.7%) 5 (50%) 68 (50.7%) 0.610
Cerebral infarct 4 (2.8%) 0 (0%) 4 (3%) 0.747
Cortical dysgenesis 6 (4.2%) 3 (30%) 3 (2.2%) 0.004
Focal cortical dysplasia 34 (23.6%) 2 (20.0%) 32 (23.9%) 0.566
Tuberous sclerosis 7 (4.9%) 0 (0%) 7 (5.2%) 0.597
Hippocampal sclerosis 7 (4.9%) 0 (0%) 7 (5.2%) 0.597
Brain tumour 5 (3.5%) 0 (0%) 5 (3.7%) 0.694
Encephalitis 8 (5.6%) 0 (0%) 8 (6%) 0.554
Interictal epileptiform discharge (IED)
Focal 45 (31.2%) 6 (60%) 39 (29.1%) 0.051
Multifocal 76 (52.8%) 1 (10%) 75 (56%) 0.007
Unilateral 55 (38.2%) 8 (80%) 47 (35.1%) 0.005
Generalized 13 (9%) 1 (10%) 12 (9%) 0.624
Table 3
Overall outcome.
Seizure-free Improved No change Sig.
3 months (144) 2 (1.4%) 48 (33.4%) 94 (65.3%) 0.056
6 months (144) 5 (3.5%) 74 (51.4%) 65 (45.2%) 0.155
2 years (144) 10 (6.9%) 89 (61.8%) 45 (31.3%) 0.000
More than 2 years (144) 5 (3.5%) 96 (66.6%) 43 (29.8%) 0.012
Table 4
Seizure outcome in adults compared with children.
Seizure-free Improved No change
Adults
3 months (81) 0 (0%) 23 (16%) 58 (40.3%)
6 months (81) 1 (0.7%) 40 (27.8%) 40 (27.8%)
2 years (81) 2 (1.4%) 45 (31.2%) 34 (23.6%)
More than 2 years (81) 2 (1.4%) 48 (33.3%) 31 (21.5%)
Children
3 months (63) 2 (1.4%) 25 (17.4%) 36 (25%)
6 months (63) 4 (2.8%) 34 (23.6%) 25 (17.4%)
2 years (63) 8 (5.6%) 44 (30.6%) 11 (7.7%)
More than 2 years (63) 3 (2.1%) 48 (33.3%) 12 (8.3%)
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freedom was deﬁned as a condition in which the patient was
seizure-free for aminimumof 1 year prior to the last postoperative
visit. If seizures reappeared in an initially seizure-free patient, the
outcome was deﬁned as non-seizure-free.
2.7. Statistical procedures
For the single predictive variable analysis using categorical
variables, the x2, Fisher’s exact, and binomial tests were applied.
The Mann–Whitney U-test was employed to compare continuous
variables. A logistic stepwise multivariate regression for variables
showing a signiﬁcant effect in a single predictive analysis was used
to identify which variables could predict the outcome indepen-
dently. Two-tailed error probabilities smaller than P = 0.05 were
considered signiﬁcant.
3. Results
3.1. Overall outcome
Overall, 10 (6.9%) of 144 patients remained seizure-free for more
than 1 year, in 89 cases (61.8%) seizures improved and in 45 cases
(31.3%) seizures did not change. The outcome of treatment in all
patients with a follow-up of 3 and 6 months as well as more than 2
years is demonstrated in Table 3, with VNS adjustment correlated
with seizure freedom in some patients. Standard cycle parameters
were changed to rapid cycle parameters in 35 (24.3%) patients, 5 of
whombecameseizure-freeaftertheadjustment.Therangeofcurrent
intensity in seizure-free patients was between 1.25 and 3mA.
Psychomotor seizures showed a signiﬁcant negative association
with outcome (P = 0.042). Unilateral interictal epileptiform dis-
charges had been recorded in 80% of patients who later became
seizure-free (P = 0.005). On the other hand, 1 patient (10%) with
multifocal IED became seizure-free. Multifocal IED showed a
signiﬁcant negative associationwith outcome (P = 0.007) (Table 2).
3.2. Outcome in relation to age
In our study, 63 patients were younger than 18 years at the time
of implantation. Of these, 8 patients (5.6%) became seizure-free(P < 0.000) and the seizures improved in 44 patients (30.6%). Of 81
patients older than 18, 2 of them (1.4%) became seizure-free.
Seizures improved for 45 of these patients (31.2%), and for 34
(23.6%) seizures did not change. The outcome after a follow-up of 3
months, 6 months and more than 2 years is demonstrated in
Tables 3 and 4. For the factor age at implantation a signiﬁcant
difference could be seen between seizure-free and non-seizure-
free patients (P = 0.026). The average age at implantation in the
seizure-free group was 16.2  10.8 (range 7–36 years), and
24.3  13.5 (3–65 years) in the non-seizure-free patients.
3.3. Outcome in relation to etiologic factors
Various types and degrees of malformation of cortical devel-
opment were observed in 44 patients (30.6%), 5 (1.5%) of whom
became seizure-free after stimulation. The MRI showed a focal
cortical dysplasia in 34 patients (23.6%). In 6 cases (4.2%) cerebral
dysgeneses such as polymicrogyria, macrogyria, hemimegalence-
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with bilateral posterior parietooccipital polymicrogyria and one
with left perisylvianmacrogyria became seizure-free (P = 0.004). In
3 other patients, 1 patient with hemimegalencephaly became
seizure-free for 4 months and 2 patients with bilateral perisylvian
polymicrogyria and band heterotopia did not improve after VNS.
3.4. Outcome in relation to AEDs
All patients were examined at regular intervals of 4 weeks for
6–9 months. During this period the antiepileptic medication
remained constant. After that AEDs have been added in case of
seizure deterioration or presence of side effects. During follow-up
the new add-on antiepileptic drug, levetiracetam had been added
to the treatment in 2 of the 10 patients who became seizure-free
(P = 0.080). In the ﬁrst case levetiracetam was added 2 months
after surgery and the patient became seizure-free thereafter. In the
second case, levetiracetam was added 1 year after the operation.
3.5. Univariate analysis
Five variables showed a signiﬁcant association with seizure-
free outcome: age at implantation (P = 0.026), multifocal IED
(P = 0.007), unilateral interictal epileptiform discharge (P = 0.005),
cortical dysgenesis (P = 0.004), and psychomotor seizures
(P = 0.042).
3.6. Multivariate analysis
Stepwise logistic regression was undertaken to investigate in a
single predictive variable analysis those ﬁve factors found to be
signiﬁcant. Three of the factors correlated independently with
successful VNS treatment: age at implantation (P = 0.026,
HR = 7.533, 95% CIs 1.275–44.494), cortical dysgenesis
(P = 0.007, HR = 0.065, 95% CIs 0.009–0.481), and unilateral IEDs
(P = 0.014, HR = 0.112, 95% CIs 0.019–0.642).
3.7. Complications
Some side effects were observed in 43 patients (30.6%). These
mostly varied from mild to moderate and disappeared after 4–6
months. Most commonly reported complications were hoarseness
in 32 patients (22.2%), coughing in 8 (5.6%) and dizziness in 4
(2.8%). In addition, in two cases the VNS cable was broken 1.5 and 2
years after implantation. These patients underwent reimplanta-
tion.
4. Discussion
Despite the increasing amount of clinical data, it is still not
possible to predict seizure-free outcome after VNS. In our study,
the presence of unilateral IED, cortical dysgenesis, and a younger
age at implantation independently predicted a seizure-free out-
come. The major ﬁnding of this study is the number of seizure-free
patients (N = 10) with more than 1 year of seizure freedom. A
literature review showed that there are only three studies in which
more than 1 year of seizure freedom was presented, and fewer
patients (2, 3 and 6 patients) were included in all three of these
studies.8–10 In our study, only 2 patients became seizure-free after
adding levetiracetam with a non-statistically signiﬁcant effect on
the outcome (P = 0.08).
4.1. Unilateral IED
Our study demonstrated that unilateral IED independently
predict seizure freedom after VNS implantation. Some studiesindicated a relationship between VNS outcome and the electrical
seizure pattern.11 The absence of bilateral IEDwas shown to have a
signiﬁcant correlation with a seizure-free outcome12; in another
study it could be seen that patientswith an onset of seizure activity
in the temporal area had a better outcome than those with frontal
or fronto-central seizure activity.11 Overall, the outcome of
epilepsy surgery showed better results when IED occurred
ipsilaterally.13,14
4.2. Cortical dysgenesis
Cortical dysgenesis encompasses a wide spectrum of brain
disorders resulting from abnormal neuronal proliferation, migra-
tion or cortical organization.15,16 A few studies reported the effect
of VNS on refractory seizures due to cortical dysgenesis.17–20
Montenegro et al. described 9 patients with parietooccipital
polymicrogyria associated with epilepsy that was intractable in 7
patients.21 Cortical dysgenesis is often associated with a high
degree of epileptogenicity. Seizure generation has been hypothe-
sized to be the consequence of incomplete cellular maturation and
pathogenic mechanisms will likely vary in mild and severe cortical
dysplastic tissues.22 With increasingly better MRI resolution, these
lesions can be readily detected in patients with cryptogenic
epilepsy. In fMRI, these lesions responded actively to simple
stimuli or tasks.23 However, in well-deﬁned epileptogenic areas
like cortical tubera or FCD, resective surgery is the preferred
treatment option.24,25 Theoretically, VNS has a widespread
inhibitory effect on the brain and, therefore, has a therapeutic
role in patients who are not ideal epilepsy surgery candidates.11
We recommend prospective VNS studies enrolling larger numbers
of patients to conﬁrm this result.
4.3. Age at implantation
The relation between the age at implantation and VNS outcome
is controversial. In agreement with our study, Wheless andMaggio
found that patients younger than 18 years of age at implantation
have a better response than those who are over 18. Murphy et al.
found that there were few adverse effects in patients younger than
age 12.26,27 These results could be explained by the fact that an
immature brain has a higher threshold for excitatory stimuli and
seizure-induced changes than an adult one. The inverse correlation
between age and the thresholds of after-discharges following
cortical stimulation is well known: the younger the patient, the
higher the thresholds. Moreover, experimental data showed that
kindling and secondary hippocampal damage is less expressed in
developing rats compared with adult animals. Moreover, electrical
VNS interferes with amygdaloidal kindling epileptogenesis in the
cat. Therefore, VNS early in the course of treatment is recom-
mended,23,28 if other therapeutic options have failed to control
seizures.
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